and the expression of the intestinal tight junction (TJ) proteins occludin and zonula occludens‐1 (ZO‐1), protects the intestinal barrier, and reduces the inflammatory response.[12] Moreover, the bioavailability of CGA is largely dependent on its metabolism by the gut microbiota, and these microbial‐derived metabolites account for 57.4% of the total intake of CGA.[13] Therefore, we hypothesized that CGA might alleviate the symptoms of PI‐IBS by interacting with the gut microbiota or exerting intestinal and neuroprotective effects. This evidence concerns the gene TJP1 and irritable bowel syndrome.